GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD
Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD
FTSE 100 pulls back as pound strengthens, but oil shares hold gains
LONDON MARKETS: FTSE 100 Pulls Back As Pound Strengthens, But Oil Shares Hold Gains
The Corporate Reputation of Pharma 2015 - The Perspective of 110 Patient Groups with an Interest in Skin Conditions - Research and Markets
The Corporate Reputation of Pharma 2015-2016 - The Perspective of 139 Patient Groups with an Interest in Diabetes - Research and Markets
The Corporate Reputation of Pharma 2015-2016 - The Perspective of 111 Patient Groups with an Interest in Hepatitis - Research and Markets
GlaxoSmithKline Starts Phase III Studies with Daprodustat
GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.